1. Introduction {#s0005}
===============

Persistent high-risk human papillomavirus (hr-HPV) infection is a necessary, but not always sufficient precursor to cervical cancer, the leading gynecologic cancer worldwide. ([@b0070]) It is estimated that 80% of sexually active women will contract genital HPV by 50 years of age. ([@b0065]) Persistent hr-HPV infections are the most significant risk factors for the development of high-grade cervical dysplasia (also known as Cervical Intraepithelial Neoplasia or CIN 2--3) and cancer ([@b0155]).

Standard-of-care management for CIN 2--3 consists of surgical therapy, which ablates or excises the cervical transformation zone. ([@b0235]) Ablative procedures consist of cryotherapy, thermal ablation or laser therapy. Excisional options include a loop electrosurgical excision procedure (LEEP) or cold knife cone (CKC), which remove one to three centimeters of cervical tissue. Although surgical therapy is highly successful in the majority of people, 5--16% of people with CIN 2--3 will have a recurrence of disease within 5 years of an excisional procedure; most recurrences will be within two years. ([@b0130], [@b0045]) In high-risk people, such as those living with HIV in low- or middle-income countries, the risk can be as high as 19--37% ([@b0270], [@b0080]).

The overall success of excisional treatments is high, and the immediate post-procedure risks, which are few, are minor. These include bleeding, infection and pain. However, there are long-term risks to consider, particularly in people of childbearing age. People who undergo excisional procedures for cervical dysplasia have an increased risk of preterm delivery, 1.56 relative risk for loop excision to 2.70 relative risk with a cold knife cone. ([@b0170]) A systematic review and *meta*-analysis which included 65,082 treated women reported that this risk increases as more cervical tissue is removed through depth of excision or repeated treatments. ([@b0170]) There is also psychological distress associated with the need for invasive procedures, ([@b0150], [@b0225]) as well as significant individual and infrastructure costs. ([@b0120], [@b0245]) The estimated cost of the common excisional procedures (cryotherapy, LEEP and cold knife cone) was estimated to cost \$112, \$407 and \$3,739) with a projected annual cost of \$75--91 million per 100,000 patients from LEEPs alone, based on 2001 US dollars. ([@b0140]) In a more contemporary analysis, the cost of cervical HPV-related disease is estimated to cost the US \$4 billion annually, as adjusted to 2004 US dollars. The development of nonsurgical, noninvasive, and patient-controlled modes of treatment have the potential to decrease the long-term morbidity and cost of treatment.

Cervical cancer is a cancer of economic, social, and educational disparities. A medical therapy option could overcome many of the barriers to surgical therapy -- desire for child-bearing, cost, health provider skill, equipment, geography, and patient fear. ([@b0340]) Ultimately, even if less efficacious than excision procedures, medical therapies have the potential to decrease cervical cancer by eliminating barriers or as an adjunctive to surgical treatment to increase the efficiency of therapy. ([@b0055], [@b0190]) Additionally, primary medical therapies would address a treatment bottleneck in both high- and low-resource settings, by allowing people to begin treatment immediately.

There are currently no topical therapies recommended to promote the clearance of hr-HPV infection or CIN however this is in large part due to the paucity of available data on the subject. This systematic review will discuss the published literature on topical therapies, exclusively those with the potential for patient self-application as a medical therapeutic alternative for the treatment of CIN 2/3.

2. Methods {#s0010}
==========

2.1. Search methods {#s0015}
-------------------

A medical librarian developed search strategies using a combination of keywords and MeSH and Emtree subject headings. As for the therapies, the search terms utilized were:" fluorouracil", "5-FU", "5-fluorouracil", "adrucil", "carac", "efudix", "efudex", "fluoro-uracile", "fluoro aracile", "fluoroplex", "fluorouracile", "tolak", "neofluor", "cidofovir", "imiquimod", "flurorophyrimidine", "curcumin", "interferon-alpha", "interferon", "antimetabolites", and "antineoplastic". For disease site and status, the search terms were "cervix uteri","cervical", "cervix", "uterine", "uterus", "endocervix", "endocervical", "intra-epithelial", "intraepithelial", "dysplasia", "cervical intraepithelial neoplasia", or "uterine cervical dysplasia". Additional keywords and Mesh terms were used for drug formulation and application method. The complete search terms included in the query are noted in Supplemental Figure 2. These were used to search PubMed via NLM, Embase via Elsevier, Web of Science, and ClinicalTrials.gov from the date of database inception to September 21, 2018, when all searches were completed.

2.2. Inclusion and exclusion {#s0020}
----------------------------

Articles were reviewed according to prospectively determined inclusion and exclusion criteria. Treatments with the potential for self-application were chosen for inclusion. In instances in which the topical therapy was applied by a medical provider, these studies were excluded. Treatments requiring or including provider-administration (injections, ablative therapies, excisional procedures, and photodynamic therapy) were excluded from the review. Animal and *in-vitro* studies were also excluded along with conference reports, conference abstracts, and editorials.

2.3. Data extractions {#s0025}
---------------------

Citations were exported to Endnote and evaluated for duplicity. An initial review of all abstracts and titles were completed by two independent gynecologists that evaluated for pertinence and applicability. Any conflicts between the two reviewers were resolved by a third gynecologist. Remaining abstracts were then be reviewed in its entirety for appropriateness based on the aforementioned inclusion and exclusion criteria. All studies that were determined applicable to the topical therapies for the treatment of CIN 2/3 were utilized for the completion of this review. We followed a systematized process, based on the PRISMA reporting standards for systematic reviews. The nature of these studies were heterogenous and lacked high quality studies. Study authors determined that this information was not amenable to a quantitative synthesis and thus the results of this research are presented as an expert narrative synthesis. The final studies included in this narrative review are outlined in [Table 1](#t0005){ref-type="table"}.Table 1Summary of Topical Therapies for the treatment of Cervical Intraepithelial Neoplasia (CIN) 2/3.StudyStudy TypeDysplasiaRegimenSample SizeDiagnostic TestingFindings**IMMUNE MODULATORSImiquimod**Lin 2012Prospective CohortCIN or VAINTwice weekly for 12 doses72Histology 6 months post-treatment51.4% with histological regression while 8.3% had progressive histologyGrimm 2012RCTCIN 2/3Titrating 1--3 vaginal suppositories over 16 weeks24(per group)4 quadrant colposcopic-guided biopsies at 20 weeks73% regression to low grade or normal vs. 39% in the placebo groupDiaz-Arrastia 2001Prospective Case seriesHSIL of vulvar, vagina or cervixApplication three times weekly for 6--16 weeks8(2 cervical dysplasia)Histology by 1 month50% with complete resolution, 25% with regression to low grade([@b0035])Retrospective case seriesCIN or VAIN already treated with surgeryTwice weekly for 8 weeks76Repeat cytology/HPV 3 mos. after treatment76.3% with normal pap smear. No histology performed.Pachman 2012RCTCIN 2/3, recur or pers CIN I1 packet every 4 days for 5 application then ablative vs. excisional therapy56Cytology +/- histology at 4 mos then q4-6 mos. Endpoint: persis/recur CIN by 2 yearsNo difference dysplasia (CIN2/3 or recurrent CIN with same HPV type) between 2 groups (25% vs. 21% in control)**Trans retinoic Acid**Weiner 1986Prospective cohortMild, mod, sev dysplasiaDaily for 4 days; 2 different concentration cohorts42Histology at 5 -- 18 months14% (2/14) and 45% (10/22) with resolution in the low and high concentrationMeyskens 1983Phase I prospective cohortMild or mod CINEscalating doses of TRA for 4 consecutive days35Clinical and colposcopic examination of side effectsNo systemic effects, mild cervical inflammation at higher doses, high vaginal toxicity at 0.484%Graham 1986Phase II prospective cohortMild, mod, sev dysplasiaCervical cap for 4 days then 2-days every 3 months for one year25Cytology and Histology50% (10/20) histologic and cytologic repression regression of diseaseDiSilvestro 2001Prospective cohortCIN 2/3Gel on sponge inside cervical cap for 4, 8 or 14 days52Colposcopic directed histology 90 days after treatment46.9% regression. 53.1% with no change.ªChen 1994RCTNROnce daily for 50 daysNR74.3% regression after two-courses of treatmentSurwit 1982Prospective CohortCIN 2/3Daily applications for 4 days18Conization of cervix 4 weeks post- treatmentReduced lesion size in 33% and complete regression in 11%Meyskens 1994Phase III RCTCIN 2/3Cervical sponge daily for 4 days then 2 days at 3 and 6 mos.301Cytology and colposcopic guided histology at 15 monthsHistologic resolution in 43% vs. 27% in CIN 2 placebo group. No difference in the CIN3 group.Ruffin 2004Prospective cohortCIN 2/34 doses daily at different dosages175Histology at 12 weeksResponse to therapy not statistically significant in all 4 dose groups**Interferon**Krause 1987Prospective CohortCIN 3Interferon gel in vaginal cup for 4 consecutive weeks9Conization after 4 weeks22% (2/9) with complete resolutionMoller 1983Prospective CohortCIN 2/3, CISInterferon gel via cervical cap2 times per week for 6 weeks6Histology at 6 and 12 wks50% (3/6) with "light dysplasia"Schneider 1995Phase II RCTCIN 2/33 concentrations of interferon gel for 28 days via diaphragm33(24 therapy vs 9 laser)Cytology and histology with HPV typing after 6 months42% (10/24) vs 89% (8/9) with resolution and 42% (10/24) vs 11% (1/9) with regressionYliskoski 1990RCTCIN or VAINVaginal gelnightly for 2 weeks, multiple courses over 1 year19(9 interferon vs 10 placebo)HPV genotyping at 16 months67% (6/9) HPV negativeChoo 1985Prospective cohortMod, sev dysplasia, CISTwice daily application of gel via vaginal applicator7 patientsColposcopy -- no histology28% (2/7) resolution, 43% (3/7) regression and 28% (2/7) with no response on colposcopy**Granulocyte-macrophage colony stimulation factor (GM-CSF)**Hubert 2010RCTCIN 1Gel applied every 3 days for 4 doses with applicator26 (15 CIN 1 and 11 controls)Plasma HPV viral load and histology at 26--30 monthsDecreased HPV viral load; no clinical response based on histology.**ANTIPROLIVERATIVE5-Fluorouracil (5FU)**Maiman 1999RCTCIN 2/3Cream applied once every 2 weeks for 6 months after excision101 (50 therapy and 51 controls)Histology at up to 18 mos28% (14/50) vs. 47% (24/51) with recurrent CIN 2/3([@b0020])Prospective CohortCIN 1,3Cervical cap daily for 7 days10Histology at 6--12 mos20% (2/10) resolution, 40% (4/10) with regression to CIN1, and 40% (4/10) with persistent CIN1/CISSillman 1981Prospective cohortVulvar, vaginal,cervical mod, sev dysplasiaCream applied nightly for 2 weeks then once monthly16Histology100% (16/16) with resolutionRahangdale 2014RCTCIN 2Cream every 2 weeks for 16 weeks60 (31 treatment vs 29 placeb0)Histology at 6 months93% (26/28) vs. 56% (15/27) with regressionPride 1982Prospective CohortVaginal/Cervical dysplasiaNightly for 10 nights via diaphragm11Conization or hysterectomy55% (6/11) with resolutionSidhu 1997RCTCIN 1/2Bio-adhesive film using applicator104 (51 with therapy vs 53 with placeboHistology at 6 months67% (32/48) and 72% (33/46) regression or resolution in the treatment and placebo group.**Cisplatin**ªNakayama 1992Prospective cohortmild/mod/sev and "microinvasive ca"Daily placement via gauze tampon for 10 days.12Histology at day 10100% with resolution in CIN group (10/10) and 50% (1/2) regression in microinvasive ca group**Iodosteric Acid**†Gleeson 1992RCTCIN 2/3Application with pessary vs. placebo for 30 nightsNRHistology at 30 daysNo clinically significant difference in the 2 groups**ANTIVIRALSCidofovir**VanPachterbeke 2009RCTCIN 2,3Gel via cervical cap once 6 weeks prior to conization48 (23 treatment vs 25 placebo)Conization61% (14/23) cidofovir vs 20% (5/25) placebo with resolutionSnoeck 2000Prospective CohortCIN 3Gel applied every other day for 3 applications15Histology within 1 month47% 7/15 with resolution, 7% (1/15) with regression to CIN I, 33% (5/15) with persistent CIN 2/3Bossens 2018Prospective cohortCIN 2,3Gel applied once per week for 3 weeks for 5 or 10 h9N/ANo clinically significant adverse events**Lopinavir and Ritonavir**Hampson 2016Prospective Cohort studyHSILVaginal pessary twice daily for 2 weeks23Cytology at 12 weeks63.6% with no dysplasia, 18.2% with low grade**Vidarabine**†Okamoto 1999Cohort studyCIN I and 2Vidarabine ointment and/or podophyllin21Cytology and Histology81% (17/21) with regressionNiwa 2003Cohort studyCIN and Stage IA1 cervical cancerRegimen not described30HPV typing by PCR10% (1/10) with resolution of HPV infection**Terameprocol**Khanna 2007Phase I/II clinical trialCIN 1 and 2/3Direct cervical application once weekly for 3 weeks7N/ANo serious adverse events noted**HORMONALSProgesterone**Hefler 2010Phase II clinical trialCIN 110 days month for 6 months40Cytology and histology30% regression vs 38.3% in the placebo**Dehydroepiandrosterone (DHEA)**Suh-Burgmann 2003Prospective Cohort studyLSILDaily for up to 6 months12Histology83% (10/13) with no dysplasia**HERBAL AND ALTERNATIVE REMEDIESAlternative Remedies**Joshi 2011Prospective cohortLSILCapsules twice daily for 12 weeks21Histology76% (16/21) with resolution to normal and 19% (3/21) unchanged.Ahn 2003RCTCervicitis, CIN 1, 2 and 34 groups (1 topical). Ointment twice weekly for 12 weeks27 (topical group)Histology74% (20/27) topical vs. 10% (4/39) control with regressionAshrafian 2015RCTCIN 1 and 23 groups (high dose, low dose, placebo) daily application for 180 days25 high dose vs 24 low dose vs 23 placeboHistology100%, 90.5% and 61% regression in high dose, low dose and placeboShukla 2009RCTHPV 16 infection +/- LSILPraneem tablet vaginally daily for 30 days20 (10 treatment vs 10 placebo)HPV 16 PCRElimination of HPV 16 in 60% (6/10)Swanick 2009Case ReportCIN 2/3Escharotic treatment 2x/weekly for 5 weeks1Cytology and colposcopyNILM pap smear at 4 and 10 mos and satisfactory colposcopy at 10 mosValencia 2011Prospective CohortLSIL cytologyOral or topical spray for 8 weeks minimum.62Treatment until improvement per cytology and colposcopyImprovement in colposcopic appearance in 74% at 12 weeksLaccetta 2015Prospective CohortASCUS or LSIL cytologyTwo cycles of daily application for 20 days356 (176 treatment vs 180 placebo)Cytology and Colposcopic evaluation at 6 and 12 mos.83.5% vs. 60% of controls with negative pap smear. 55.4% vs. 24.7% of controls with no colpo lesionsStentella 2017Retrospective case-controlCIN 1/2Carbodymethyl beta-glucan gel999Cytology, histology, colposcopic changesNonsignificant regression of CIN 2Stefani 2014Prospective CohortCIN 1Bovine colostrum containing vaginal tablets256Histology at 6 months75.5% regression†Bottino 1991RCTNRCream applied vaginally40 in dysplasia groupNR70% (28/40) efficacy in dysplasia patients[^1][^2][^3]

3. Results {#s0030}
==========

The collective database searches yielded a total of 1,043 citations, with an additional 13 citations found by searching ClinicalTrials.gov. The 1056 total citations were exported to Endnote and 288 duplicates were removed, leaving 768 unique citations found in all searches. Two reviewers (LR, ND) screened titles and abstracts for relevance, excluding 579 irrelevant studies. A third reviewer (KM) reviewed any conflicts. The full text of the remaining 189 papers were then reviewed for relevance and a further 145 studies were exclude for wrong study designs, interventions, outcomes, or patients. Ultimately, 41 studies were included in the review and data extracted. [Fig. 1](#f0005){ref-type="fig"} provides a PRISMA diagram showing the process of study inclusion. [Table 1](#t0005){ref-type="table"} summarizes the types of therapies that have been studied to date.Fig. 1The PRISMA diagram for database search results of topical therapies for the treatment of Cervical Intraepithelial Neoplasia (CIN) 2/3.

3.1. Immune-modulators {#s0035}
----------------------

Imiquimod functions at the TLR7 receptor to stimulate the innate immune system and increase production of the cytokines interferon α, interleukin 6 (IL-6), and tumor necrosis factor α (TNF-α). Imiquimod is used to treat genital warts and vulvar/vaginal dysplasia. It has also been studied as a medical therapy for high-grade squamous intraepithelial lesions of the cervix. ([@b0090], [@b0215], [@b0185], [@b0035]) Imiquimod is typically used as a topical cream with concentrations from 1% to 5% applied three to seven times per week for eight to 16 weeks. Local reactions can include erythema, pruritis, excoriation, erosion, edema, scabbing, or crusting. Though used topically with minimal systemic absorption, imiquimod therapy can produce systemic reactions such as myalgia, headache, fatigue, and nausea. ([@b0085]) A review of its use in cervical, vulvar, and vaginal dysplasia also described mild to moderate local and systemic side effects but overall it was well-tolerated. ([@b0050]) In a review of 3 studies in which imiquimod was utilized for the treatment of CIN, side effects were well tolerated by patients; only 2 out of 132 patients discontinued therapy due to side effects. ([@b0050])

De Witt et al reviewed 3 studies and only one was a randomized controlled trial. This randomized controlled trial was conducted by Grimm et al and showed that a 16-week course of self-applied dose escalating intravaginal imiquimod treatment of CIN 2--3 led to histologic regression and HPV clearance (73% versus 39%, p \< 0.05 for histologic regression and 60% versus 14%, p \< 0.05 for HPV clearance). ([@b0090]) More than 90% of participants in the imiquimod arm reported both local and systemic (flu-like symptoms and fatigue) symptoms however no participants experiences high-grade side effects and only one discontinued therapy ([@b0090]).

There are active studies evaluating the use of imiquimod. The "Topical Imiquimod treatment of high-grade Cervical intraepithelial neoplasia" (TOPIC) trial was a 2015 study designed to randomize patients into an imiquimod arm and an immediate treatment arm with excision however was prematurely stopped in 2017 due to poor enrollment. The study design was then converted to a non-randomized efficacy trial entitled TOPIC-3. A related study, TOPIC-2, is a non-inferiority randomized single blinded study in women with recurrent/persistent CIN after previous excisional treatment. ([@b0320]) The study anticipates recruiting 433 patients to establish non-inferiority to recurrent excisional procedure. It is estimated to complete in 2020.

Other immune-modulating approaches have included *trans*-retinoic acid or interferon with both being used to treat viral infections and cancers. Trans-retinoic acid is a metabolite of Vitamin A and plays a key role in mucosal immune responses. Interferons are cytokines produced by the immune system when triggered by viral infection or other immune processes. They have both been studied on low-grade and high-grade CIN since the 1980s with little progress in the development of a viable agent. ([@b0330], [@b0195], [@b0160], [@b0200], [@b0230], [@b0075], [@b0040], [@b0345], [@b0240]) A Cochrane review of 5 studies utilizing retinoids (given orally and topically) for the treatment of CIN showed that retinoids are not effective in preventing progression in any grade of CIN ([@b0110]).

Studies are notable for the delivery of medication through sponges in cervical caps and vaginalettes (delivery agents soaked in gel) which may be useful in the development of self-applied therapies. ([@b0075], [@b0300], [@b0060], [@b0265]) Additionally, a new approach has been the local application of GM-CSF (granulocyte--macrophage colony-stimulating factor), a cytokine produced in response to immune stimuli, in order to increase numbers of antigen-presenting cells (APCs) in CIN lesions. A Phase 1b study of 15 people with CIN 1 reported favorable toxicity, and significant increases in APCs and cytotoxic T-lymphocyte infiltration of cervical biopsies ([@b0115]).

3.2. Anti-Proliferative therapies {#s0040}
---------------------------------

5-fluorouracil (5-FU) is an anti-metabolite which has been used widely to treat malignancies such as colon cancer as well as dermatologic conditions. ([@b0015], [@b0315], [@b0280]) The primary mechanism of 5-FU is to block synthesis of thymidine and prevent DNA replication. For decades, observational studies have demonstrated efficacy in using topical 5-FU for treatment of HPV-related diseases (e.g., genital warts, and vulvar and vaginal dysplasia). ([@b0315], [@b0335], [@b0280]) Previously, 5-FU topical treatment was limited by side effects, including burning, erythema, erosion, pain, and chronic ulceration, because standard treatment regimens required multiple daily applications. ([@b0165]) However, limiting the application of 5-FU to biweekly dosing or decreasing the concentration of 5-FU has shown improved tolerance. ([@b0190], [@b0220])

Small proof-of-concept studies of 5-FU for treatment of CIN were initiated in the 1980s. ([@b0255], [@b0020]) Subsequently, Maiman et al. studied intravaginal 5-FU to prevent recurrence of CIN 2--3 after excisional treatment in HIV-infected people. ([@b0190]) People who self-applied 2 g of 5% intravaginal 5-FU every two weeks for up to six months were less likely to develop a CIN 2--3 recurrence at 18 months than those in the observation arm (31% vs. 8%, p = 0.014[)]{.smallcaps}. ([@b0190]) Rahangdale et al used a similar dose schedule (2 g every two weeks) for 16 weeks for primary treatment of CIN 2. ([@b0220]) ([Table 1](#t0005){ref-type="table"}) In this study, 60 people without HIV were randomly assigned to self-applied 5-FU (8 total doses) versus observation. Those in the 5-FU group were more likely to experience disease regression (CIN 1 or normal) (93% 5-FU versus 56% control; p = 0.01). The composite outcome of histology, Pap smear, and hr-HPV results was more likely to be normal in the 5-FU group than the observation arm (RR 2.25, 95% CI 1.05--5.09). In both studies people tolerated the biweekly dosing, and although mild side effects (e.g. bleeding, irritation, and discharge) were common, no moderate or severe side effects were reported ([@b0220]).

A recent case series highlights the role of 5-FU in clinical practice for patients seeking a LEEP alternative in both recurrent and primary CIN 2/3. ([@b0055]) A Phase 1 study of feasibility of combination therapy with topical 5-FU with imiquimod for women with CIN 2--3 is estimated to complete in 2020 (ClinicalTrials.gov Identifier: NCT03196180).

3.3. Antivirals {#s0045}
---------------

Cidofovir is an acyclic nucleoside phosphonate derivative with broad-spectrum anti-DNA virus activity and an extended half-life, allowing for infrequent application. It is used as treatment for vulvar and non-genital HPV lesions as well as for viruses such as herpes, Mollusca contagiosa, and adenovirus. Studies of cidofovir gel have shown promising results for clearance of CIN with minimal toxicity. ([@b0275], [@b0325], [@b0030]) Previous dosing regimens have ranged from three times every other day to three times per week to once per week. Van Pachterbeke, et al, reported a randomized, placebo-controlled trial of 2% cidofovir gel applied three times in one week in 48 people with CIN 2--3. Subsequent cervical biopsy demonstrated that 61% cidofovir versus 20% placebo (p \< 0.01) demonstrated regression or clearance of CIN 2--3 ([@b0325]) ([Table 1](#t0005){ref-type="table"}).

Lopinavir and ritonavir, a combination oral HIV protease inhibitor (Lopimune) has been studied as potential treatment for CIN. ([@b0095], [@b0180], [@b0025]) Hampson, et al conducted an exploratory study of 23 HIV-uninfected people with hr-HPV and HSIL cytology. ([@b0100]) Each person self-inserted one lopinavir/ritonavir combination capsule per vagina twice a day for two weeks. Cytology and hr-HPV testing at 12 weeks showed 82% regression in cytology results from HSIL to either low grade or no dysplasia; 78% of these were confirmed by histology. The therapy was well-tolerated with local side effects of vaginal discharge and irritation, and systemic side effects of headache, nausea, and abdominal pain. ([@b0100])

Other antivirals being studied include Vidarabine and Terameprocol. Vidarabine, a DNA polymerase inhibitor used for treatment of HSV, has been applied successfully as an ointment in conjunction with podophyllin or compared to 5-FU for treatment of HPV infection in studies of ten to 28 people. ([@b0205], [@b0210]) Terameprocol (*meso*-tetra-o-methyl nordihydroguaiaretic acid, EM-1421) is a transcription inhibitor that selectively interferes with HPV viral genes E6 and E7. A phase 1 study of people with CIN 1--3 treated with terameprocol demonstrated safety and a maximum tolerated dose of 1% and 2% ointments ([@b0210], [@b0135]).

3.4. Hormonal {#s0050}
-------------

Hormones have been studied as topical therapy for CIN 1. Though there is growing interest in developing treatment for CIN 1, these HPV-related lesions are usually observed and not routinely treated with surgical therapy. ([@b0235]) Vaginal progesterone has previously been shown to increase the vaginal presence of Langerhans cells, which are critical to the local immune response to HPV. People with CIN 1 were treated with intravaginal micronized progesterone suppositories (400 mg) inserted daily for ten days per month for six months. The progesterone group experienced less histologic regression (30%) than the control group (38%) (HR 3.8, 95% CI 1.8--8.3). ([@b0105]) Dehydroepiandrosterone (DHEA) is an adrenal steroid with immune modulation and tumor inhibition functions. A pilot study of 12 people with CIN 1 treated with intravaginal DHEA for three months reported regression in 83% (10/12) and was well-tolerated. ([@b0295]) No hormonal therapies have been studied as alternative therapies for CIN 2--3.

3.5. Herbal/alternative {#s0055}
-----------------------

A variety of alternative herbal or non-pharmacologic options have been studied for treatment of HPV and CIN with mixed results. A prospective randomized placebo controlled trial study of CIN 1--2 treated with self-applied diindolylmethane vaginal suppositories found that treatment groups at 100 mg/day and 200 mg/day reported regression of 91% (95% CI 70--99%) and 100% (95% CI 82--100%), respectively, compared to placebo 61% (95% CI 36--83%). ([@b0010]) However, the distribution of CIN 1 and CIN 2 was not described. Histologic regression was not defined, and participants with normal appearing colposcopy were not biopsied. ([Table 1](#t0005){ref-type="table"}) A case report of use of *Sanquinaria canadensis* (bloodroot) used as escharotic treatment has described successful treatment of CIN 2--3 in a 20-year old ([@b0305]) A retrospective study of beta-glucan included CIN 2--3 lesions and did not show benefit ([@b0290]).

Studies of green tea extract, *Azadirachta indica* (neem), beta-glucan, bovine colostrum, curcuma (tumeric) and glucyrrhizinic acid (licorice root) have demonstrated tolerability and possible efficacy in treatment of HPV infections or CIN 1. ([@b0290], [@b0005], [@b0125], [@b0250], [@b0175], [@b0285], [@b0310]) Ahn et al. in 2003 in an RCT found that application of a green tea cervical ointment twice weekly for 12 weeks results in the regression of 74% (20/27) of those in the treatment group versus 10% (4/39) in the control group however, the cohort contained with cervicitis, CIN 1, 2 and 3 thus limiting the inferences on efficacy that could be made from this group. ([@b0005]) The prospective study of glycyrrhizinic acid had participants using an oral or topical spray until there was improvement as noted on pap smear and colposcopy but not necessarily histology. ([@b0310]) There next two studies utilizing beta glucan with mixed results. ([@b0290], [@b0175]) Laccetta et al. described women with ASCUS and LSIL cytology and found a significant regression of visual colposcopic lesions (55% v. 25%) meanwhile Stentella et al. found a nonsignificant difference in a group of women with CIN 1 or 2. ([@b0290], [@b0175])

A 2009 study of praneem, the seed extract of *Azadirachta indica,* reported high risk HPV 16 elimination in 60% (6/10) in the treatment compared to 10% (1/10) in the placebo group. ([@b0250]) A single study evaluating the effect of curcuma (tumeric) vaginal capsules in women with LSIL cytology found 76% resolution of dysplasia (16/21) however, there was no control group for comparison. ([@b0125]) A pilot study of bovine colostrum tablets in women with CIN 1 found 75% regression of lesions based on histology. Studies of herbal remedies were either small pilot, feasibility, or proof of concept studies that demonstrated possible efficacy but conclusions remain elusive.

4. Discussion {#s0060}
=============

There has been a long-standing and continued interest in the development of a safe, effective topical therapy for treatment of CIN and HPV. A medical therapy option could overcome many of the barriers to surgical therapy -- desire for child-bearing, cost, health provider skill, equipment, geography, and patient fear. ([@b0340]) In this review, we have summarized the available data on immune modulators (imiquimod, transretinoic acid, interferon and GM-CSF), anti-proliferative therapy (5-Fluorouracil), antivirals (cidofovir, lopinavir/ritonavir, vidarabine and terameprocol), hormonals (progesterone, DHEA) and herbal supplements. Overall, the randomized trials of immune-modulating (imiquimod), anti-proliferative (5-FU), and anti-viral (cidofovir) therapies have had the most promising results, but there is still more need for study.

Of the immune modulators, there has been little progress with transretinoic acid and interferons for a viable agent. The metanalysis of the 5 retinoids have not found them to effective. The GM-CSF study is in its infancy as a Phase 1b study. Imiquimod shows the most promise in this group. There is no conclusive data at this time but multiple studies using imiquimod for the treatment of CIN 2--3 as primary therapy or in conjunction with HPV vaccines are ongoing, specifically the TOPIC-2 and TOPIC-3 trial. ([@b0145]) The results of both of these studies will better inform our knowledge of imiquimod as topical therapy in primary and recurrent cervical dysplasia compared with excision therapy.

5-FU, an antiproliferative agent, has been limited by its side effect profile in the treatment of other sites. Modified regimens have shown better patient tolerance in the treatment of recurrent and primary cervical dysplasia. ([@b0055], [@b0190], [@b0220]) There is interest from patients in using this therapy as evidenced by the recent case series featuring 25 women. There is also a phase I study of feasibility using combination therapy of topical 5-FU with imiquimod. However, more research is still needed to understand the potential of this agent as a treatment for CIN 2/3.

Of the antivirals, cidofovir has demonstrated the most promising results largely based on the van Pachterbeke randomized control trial which demonstrated regression of CIN 2--3. The work on terameprocol is early with information arising from a Phase 1 trial. Vidarabine at this time has only been used in conjunction with other topical treatments. Only an exploratory analysis is available for lopinavir and ritonavir and more research is needed on this modality.

No conclusions can be made regarding utility of hormonal and herbal therapies due to study design, inclusion criteria or limited sample size. The progesterone and DHEA studies enrolled participants with low grade dysplasia (CIN 1) where standard of care is observation. This was a similar concern in the diindolylmethane, an herbal therapy, where participants had either CIN I or 2 and the distribution of disease was not described. Beta gluten is not effective and there is only a singular report of using sanquinara canadensis.

Limitations of this review include the low quality of clinical studies, few randomized controlled trials, and small sample sizes showing nonsignificant results. Regimens and inclusion criteria often varied so results were not comparable or generalizable. Strengths of this paper include that this was a standardized review using reproducible methods on a unique contemporary topic. The review highlights our current understanding of the topic in order to guide future directions for research on topical therapies for HPV or CIN.

Important aspects of a topical therapy to consider in the development of future therapies for treatment of HPV or CIN are safety, efficacy, delivery, and accessibility. Ideally, a topical therapy would be patient-controlled though either provider- or self- administered methodologies continue to be studied. All studies must have rigorous assessment of safety including monitoring for local and systemic adverse events and consideration of fetal risk with unplanned pregnancy. An observation period of six months with careful screening and follow up is considered reasonable when considering risk of progression. ([@b0260]) Sample size calculations must consider a threshold for efficacy which allows topical therapy to be comparable with current standard surgical options. Delivery methods ranged from a capsule or suppository to inserting the cream via vaginal applicator, sponge, pessary, or ring. As topical therapies are developed, the ease of administration and feasibility of the delivery method is critical to patient acceptance. A final consideration is accessibility. Any product in development will require extensive study including cost in order to achieve regulatory approval for sale in the market. This cost may make topical therapy unfeasible for high-risk, under-insured individuals who are most at risk for developing cervical cancer. Of the therapies described, imiquimod and 5-FU are already in use as topical therapies, have generic formulations, and have been studied as self-applied preparations. There may be an advantage to exploring therapies that can be procured at a lower cost for ease of scale up.

5. Conclusion {#s0065}
=============

At this time, there is no option with sufficient clinical trial evidence or proven efficacy to recommend topical therapy as a primary treatment for HPV infection or CIN. Unanswered questions about topical therapies include effectiveness outside of the research setting, patient acceptability, and long-term efficacy. But there is potential that by combining differing mechanisms of action (e.g. immune modulation and anti-proliferative therapy), neoadjuvant or adjuvant approaches to surgery, and/or in conjunction with HPV vaccines, more effective and accessible treatment regimens will be created with a lower risk profile. This approach may also be useful for providing options to people desiring alternative or less-invasive management, and be readily available in settings where there are treatment delays or limited access. While surgical therapy is the gold standard and is highly effective in treating CIN 2--3, an effective topical therapy may provide an accessible additional option in our cancer prevention toolkit.
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[^1]: ªIn these studies, only an abstract was available in English.

[^2]: †In these studies, only an abstract was available for review.

[^3]: RCT = randomized controlled trial; CIN = Cervical Intraepithelial Neoplasia, VAIN = Vaginal intraepithelial neoplasia, HSIL = High grade intraepithelial lesion, LSIL = Low grade intraepithelial lesion, CIS = carcinoma in situ, ASCUS = atypical squamous cells or unknown significance, mos = months, ca = carcinoma, NR = not reported.
